Seattle Genetics, Inc. today will present interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate in development for the treatment of B-cell malignancies, at the American Society of Clinical Oncology 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL.
http://ift.tt/1ry5Qcj
http://ift.tt/1ry5Qcj
No comments:
Post a Comment